Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher clinically significant response: important change As defined by each… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in leaving the study early: Overall tolerability Leaving the study… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Behavioural problems: agitation or aggression · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS may leads to higher adverse events: Sedation Number of participants with… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
VALPROATE + ANTIPSYCHOTICS showed no clear difference in adverse events: Weight gain Number of participants with weight gain compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome compared with COMBINATIONS: f. OLANZAPINE + MAGNESIUM VALPROATE (very low certainty).
1 finding from 1 review
Adverse effects · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects compared with COMBINATIONS: f. OLANZAPINE + MAGNESIUM VALPROATE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · patients with psychosis‐induced aggression or agitation
2 findings from 1 review
Adverse effect: any serious, specific ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
1 finding from 1 review